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Abstract
Epitopes from all available full-length sequences of yellow fever virus (YFV) and dengue fever virus (DENV) restricted by
Human Leukocyte Antigen class I (HLA-I) alleles covering 12 HLA-I supertypes were predicted using the NetCTL algorithm. A
subset of 179 predicted YFV and 158 predicted DENV epitopes were selected using the EpiSelect algorithm to allow for
optimal coverage of viral strains. The selected predicted epitopes were synthesized and approximately 75% were found to
bind the predicted restricting HLA molecule with an affinity, KD, stronger than 500 nM. The immunogenicity of 25 HLA-
A*02:01, 28 HLA-A*24:02 and 28 HLA-B*07:02 binding peptides was tested in three HLA-transgenic mice models and led to
the identification of 17 HLA-A*02:01, 4 HLA-A*2402 and 4 HLA-B*07:02 immunogenic peptides. The immunogenic peptides
bound HLA significantly stronger than the non-immunogenic peptides. All except one of the immunogenic peptides had KD
below 100 nM and the peptides with KD below 5 nM were more likely to be immunogenic. In addition, all the immunogenic
peptides that were identified as having a high functional avidity had KD below 20 nM. A*02:01 transgenic mice were also
inoculated twice with the 17DD YFV vaccine strain. Three of the YFV A*02:01 restricted peptides activated T-cells from the
infected mice in vitro. All three peptides that elicited responses had an HLA binding affinity of 2 nM or less. The results
indicate the importance of the strength of HLA binding in shaping the immune response.
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Introduction
The Flaviviridae family includes several important human
pathogens. These arboviruses include Dengue (DENV), Yellow
fever (YFV), West Nile Virus (WNV) and Japanese Encephalites
(JEV). All Flavivirus are enveloped, single-stranded RNA (+) viruses
coding for a polyprotein precursor of approximately 3,400 amino
acids, which is cleaved into three structural (capsid, C; precursor
membrane and membrane, prM/M; envelope, E) and seven
nonstructural proteins (NS1, 2a, 2b, 3, 4a, 4b and 5) [1,2].
Flavivirus infection, in general, elicits long-lasting immunity.
Accumulated evidence indicates that neutralizing antibody
responses are associated with protection, and increasing evidence
suggests that T-cell CD4
+ and CD8
+ responses also play critical
roles reducing morbidity and mortality. The T-cells can mediate
protection against Flavivirus by CD4
+ helper stimulation of B-cells




+ cells have been shown to be essential for
protection against WNV, and CD8
+ T-cells have been shown to
provide protective immunity against DENV [3,4,5,6,7,8] and YFV
infections [9,10].
Flavivirus, as other RNA viruses, has a relatively high mutation
rate and uses this mechanism to evade the host immune responses.
In particular, DENV has four different serotypes and immuno-
logical memory responses, either B- or T-cell, have been shown to
be involved in DENV pathogeneses.
Only few vaccines are currently available against Flavivirus,
among these are the attenuated virus vaccines for YFV and the
inactive viral protein formulation for JEV. No DENV vaccine is
available for clinical use [7]. The virus-based YFV vaccines are
associated with several adverse side effects and frequent fatal
reactions [11,12], while the JEV vaccine is relatively weak and
prone to induce allergic reactions [13,14,15,16]. Taken together,
this indicates the need for development of novel and better
Flavivirus vaccines.
Recent advances on epitope discovery and antigen delivery
technologies have enabled the development of broadly effective
epitope based vaccine formulations. Epitope vaccines are
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26494potentially safer since they focus the immune response towards
defined epitopes associated with protection, thereby minimiz-
ing cross-reactions with the potentially pathogenic epitopes
[17,18,19,20,21,22]. The objective of this study was to identify
HLA-I restricted epitopes covering 12 HLA-I supertypes (A1, A2,
A3, A24, A26, B7, B8, B27, B 39, B44, B58 and B62) within
conserved regions across all four DENV serotypes and YFV
strains. The bioinformatics approaches for selection of the
epitopes that provide optimal strain coverage were described
previously [23] and the HLA-I binding affinity of the selected
peptides were determined using conventional biochemical
binding assays [24,25]. In addition, the immunogenicity of the
A2, A24 and B7 HLA-I supertype epitopes were determined in




The HLA-I epitope predictions were performed on the basis of
a dataset consisting of all strains of YFV and DENV that were fully
sequenced in May 2006 and available in the GenBank or RefSeq
databases. Epitopes restricted to any of the A1, A2, A3, A24, A26,
B7, B8, B27, B 39, B44, B58 and B62 supertype representatives
were predicted using an inhouse version 1.0 of the NetCTL method
including prediction for the A26 and B39 supertypes [26]. In the
NetCTL method, each possible 9mer peptide in a protein is
assigned a score based on a combination of proteasomal cleavage,
TAP transport efficiency, and HLA-I binding affinity, with the
highest weight assigned to HLA-I affinity.
For YFV, we selected the 16 top-scoring 9mer peptides per
supertype for each of the 12 fully sequenced YFV genomes:
NC_002031 AY640589 AY603338 AY572535 U54798
AF094612 U21055 U21056 X03700 U17067 U17066 X15062.
Next, the EpiSelect algorithm was used for selecting a number of
predicted epitopes, which together constitute a broad coverage of
all strains. The EpiSelect algorithm has been described in detail
previously [23]. Briefly, it aims at selecting a number of epitopes
in a way so that the number of selected epitopes in the viral strain
with the fewest selected epitopes is as high as possible.
Application of the EpiSelect algorithm identified 179 unique
candidate epitopes, which are present on average in at least 11
out of the 12 genomes.
For DENV, the 15 top-scoring 9mer peptides per supertype were
selectedforeach ofthe 36fullysequencedDENVgenomesDENV-1:
NC_001477 AY762084 AB189121 AY277664 AF311958
AF226685 AY145121 AB074761 U88537, DENV-2: NC_001474
AY702038 AY702035 AY858036 AY744147 AB122020 AB189124
AF169688 AF169685 AF169682 AF169679 AF276619 AF119661
AF022439 AF022436 M29095, DENV-3: AY923865 AY858039
AY648961 AB189127 AY662691 AY099337 AF317645 AY947539,
DENV-4: AY762085 AF326573 AF375822. Application of the
EpiSelect algorithm identified 158 unique candidate epitopes, which
are present on average in at least 35 of the 36 genomes.
Peptides
The 9mer peptides were synthesized by standard 9-fluorenyl-
methyloxycarbonyl (FMOC) chemistry, and purified by reversed-
phase high-performance liquid chromatography (at least 80%,
usually .95% purity) and validated by mass spectrometry (Shafer-
N, Copenhagen, Denmark). Peptides were distributed at 500 mg/
vial and stored lyophilized at 220uC until use. Peptides were
dissolved at 2 mg/mL just before use with 10% (v/v) DMSO
(Sigma).
Biochemical peptide-HLA-I binding assay
The biochemical assay for peptide–HLA-I binding was
performed as previously described [24,25]. Briefly, denatured
and purified recombinant HLA heavy chains were diluted into a
renaturation buffer containing HLA heavy chain, b2-microglobu-
lin and graded concentrations of the test peptide, and incubated at
18uC for 48 h allowing equilibrium to be reached. We have
previously demonstrated that denatured HLA molecules can de
novo fold efficiently, however, only in the presence of appropriate
peptides [27]. The concentration of peptide–HLA complexes
generated was measured in a quantitative enzyme-linked immu-
nosorbent assay and plotted against the concentration of peptide
offered [24]. Because the effective concentration of HLA (3–5 nM)
used in these assays is below the equilibrium dissociation constant
(KD) of most high-affinity peptide–HLA interactions, the peptide
concentration leading to half-saturation of the HLA is a
reasonable approximation of the affinity of the interaction. An
initial screening procedure was employed whereby a single high
concentration (20,000 nM) of peptide was tested. If no complex
formation was found, the peptide was assigned as a non-binder to
the HLA molecule in question, conversely, if complex formation
was found in the initial screening, a full titration of the peptide was
performed to determine the affinity of binding to HLA.
Animals and immunization protocols
Transgenic mice expressing either HLA-A*02:01 [20], HLA-A
*24:02 (Lemonier et al., unpublished) or HLA-B*07:02 [21] were
used in the immunization protocols. They were bred and
maintained in the Johns Hopkins University School of Medicine
Animal Facility. Specific pathogen-free colonies were maintained
in a helicobacter-negative mice facility. HLA expression of the
experimental transgenic mice was evaluated by flow cytometry
using anti HLA-A2 PE (BD Biosciences Pharmigen), anti HLA-
A24 PE (MBL) or anti HLA-B7 FITC (Abcam). Mice were
immunized subcutaneously (tail base) twice, two to three weeks
apart, with 100 mL of pool of peptides (1 mg per peptide) dissolved
in PBS and emulsified in TiterMax (CytRx Corporation). Control
animals were immunized with DMSO dissolved in PBS and
emulsified in TiterMax. Different immunization pools were used
according to the transgenic mice and the organism by which the
epitopes were predicted from (Table S1). For each experiment,
nine mice where immunized with the peptide pools, while three
naı ¨ve mice were used as controls. Immunization with YF vaccine
was also performed subcutaneously with three doses of 10
4 plaque
forming units (PFU) of the attenuated virus, at two weeks interval.
The presence of the HLA transgene in each mouse was
confirmed by PCR during breading stages. However, the
expression of the HLA gene in this strain of mice is unstable
and therefore we screened all the mice with immune staining and
flow cytometric analyses and selected for the immunization
experiments only the mice that presented high levels of HLA
protein expression.
Ethics Statement
All experiments were approved by the Johns Hopkins Animal
Care and Use Committee under protocol number MOO7M78.
ELISPOT assays for enumeration of IFN-c spot-forming
cells (SFC)
Two weeks after the last immunization, the mice were sacrificed
and their spleens removed. Splenocytes were isolated and red cells
were lysed with ACK buffer (Pierce). CD4
+ cells were depleted
using anti mouse CD4 microbeads and LD columns according to
Yellow Fewer and Dengue Viruses Epitope Discovery
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26494the manufacturermanual (Myltenyl). The CD4-depleted splenocytes
were dissolved incomplete RPMI1640 medium (supplemented with
10% v/v fetal bovine serum (FBS), 100 U/mL penicillin/strepto-
mycin, 2 mM Lglutamine, 50 mM 2-mercaptoethanol and 1 M
HEPESbuffer).IFN-cELISPOT assayswereperformedbyusingan
ELISPOT set according to the manufacturer’s protocol (BD
Biosciences Pharmingen). Initially, the ELISPOT plates were coated
with anti-IFN-c at 5 mg/mL and incubated at 4uC overnight. The
plates wereblocked with RPMI 1640 containing 10% FBS for 2 h at
room temperature. Then, each peptide was added into ELISPOT
plate at 10 mg/mL, 1 mg/mL and 0.1 mg/mL in complete RPMI.
After that, CD4-depleted splenocytes from either immunized or
control micewere platedat0.5to 1610
6 cells per wellandincubated
for 16–18 hs at 37uC, 5% CO2. Media only and concanavalin A
(Sigma) were used as negative (background) and positive control
respectively. The plates were washed and incubated with biotiny-
lated anti-IFN-c for 2 h at room temperature, followed by HRP-
conjugated avidin for 1 h at room temperature. Reactions were
developed with AEC substrate (BD Biosciences). IFN-c spot forming
cells (SFC) were enumerated with the Immunospot Series 3B
Analyzer ELISPOT reader, using the Immunospot software version
3.0 (Cellular Technologies Ltd). The data shows the number of
SFC/10
6 cells. The peptides were considered T-cell epitopes if (i)
they elicited IFN-c SFC minus background greater than 10; and (ii)
IFN-c SFC minus 2 standard deviations (SD) must be greater than
the background (negative control) plus 2 SD.
YF vaccine
The human YF vaccine, composed of attenuated 17DD YF
virus, was a generous gift from Dr. Ricardo Galler (Oswaldo Cruz
Foundation, Rio de Janeiro, Brazil). The vaccine was reconstituted
with chilled PBS, kept in an ice bath, and used for immunization
of mice within 4 h of reconstitution.
Statistics
Wilcoxon rank sum tests and Fishers exact tests were performed
using the commands wilcox.test(), and fisher.test() implemented in
R stats package (http://sekhon.berkeley.edu/stats/html/00Index.
html).
Results
Flavivirus HLA-I binding peptides
Yellow fever epitopes: 179 YFV peptides covering 12 HLA-I
supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B 39, B44, B58
and B62) were selected using NetCTL and EpiSelect. 171 of these
could be synthesized and were tested for binding to their respective
HLA-I. 121 (71%) of these were found to bind to their predicted
restricting HLA-I element with a KD stronger than 500 nM. For a
peptide to be immunogenic, it is generally considered a prerequisite
that it binds its HLA-I molecule with a KD below 500 nM, since it
has been shown that more than 90% of the peptides recognized by
CD8
+ T-cells bind with a KD below this threshold [28].
Dengue epitopes. 158 DENV peptides, which together
represents all four serotypes and cover the 12 HLA-I supertypes
were selected using same procedure as for the YFV epitopes. 147
were synthesized and 116 (79%) were found to bind with a KD
below 500 nM. A schematic diagram of the selection scheme is
shown in figure 1.
All the peptide sequences along with their binding affinities for
the HLA-I alleles were deposited at the Immune Epitope Database
(IEDB) (http://www.immuneepitope.org/) and are shown in
Table S2.
Immunogenicity of the A*02:01, A*24:03 and B*07:02
binding peptides
The immunogenicity of peptides binding to representatives of
the A2, A24 or B7 HLA-I supertypes with high affinity was tested
in transgenic mice models (Table S1). The animals were
immunized with these peptides and the T-cell immune responses
tested individually by ELISPOT assays as described in materials
and methods. The immunogenicity of 82 peptides from both YFV
and DENV comprising 25 A*02:01, 28 A*24:03, 28 B*07:02
binders and one non-binding peptide were tested.
Among the A*02:01 binding peptides, 17/25 (68%) were able to
elicit a significant immune response under this immunization
protocol in at least two individual animals (Table 1). No significant
responses were observed in negative control mice or against the
HLA non-binding peptide (LVAGGLLTV). The binding affinity
was found to be significantly correlated with eliciting responses
(p=0.01, Wilcoxon test). When considering the peptides with a
measured affinity below 5 nM to HLA-A*02:01, 12/14 (86%) of
the peptides elicited a response which was significantly more than
the 5/12 (42%) of the poorer binders (p,0.05, Fishers exact test).
Among the A*24:03 binding peptides, 4/28 (14%) were able to
elicit a significant immune response in at least two individual
animals (Table 2). We were not able to use exactly the same A24
allele for the binding assays and the animal studies, but the
specificity of the two molecules is predicted to be very similar
(http://www.cbs.dtu.dk/biotools/MHCMotifViewer/). When im-
Figure 1. Schematic diagram of the epitope discovery scheme. In addition to the 237 good binders, 5 weak binders and one non-binder was
also tested in this study for comparison, but these are not included in the figure.
doi:10.1371/journal.pone.0026494.g001
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A*24:03, 1/3 (33%) elicited a significant response, whereas a
response was observed for only 3/25 (12%) of the peptides binding
with an affinity above 5 nM. Here, we hence also find that the
likelihood of inducing a CTL response was highest for the
strongest binding peptides. The difference between the two groups
was not, however, found to be statistically significant (p=0.27,
Fishers exact test).
Among the B*07:02 peptides, 4/28 (14%) were able to elicit
detectable responses in the B*07:02 mice (Table 3). None of the
five peptides with binding affinities below 5 nM induced an
immune response. Three of the fourteen peptides (21%) with
affinities between 5 and 100 nM induced immune responses. The
correlation between affinity and immune response was neither
statistically significant when using Wilcoxons test, nor Fishers
exact test with at affinity threshold of 5 nM. One of the nine
peptides with a binding affinity above 100 nM elicited a response,
however, it appears to be an outlier, since the peptide’s measured
affinity for the B*07:02 molecule is 6,769 nM. The peptide was
originally predicted to bind to B*07:02 with an affinity of 328 nM.
Using the latest version 2.4 of NetMHCpan (/www.cbs.dtu.dk/
services/NetMHCpan/), the peptide is predicted to bind to
B*07:02 with an affinity of 3,529 nM. Given this very low binding
affinity to B*07:02 it seems likely that this peptide is restricted by
another peptide presenting molecule. Discarding this outlier, we
find for B*07:02 that 3 out of the 19 peptides with an affinity
stronger than 100 nM elicit a response where this is the case for
none of the 9 peptides with an affinity weaker than 100 nM. The
fraction of responding peptides as a function of the affinity is
summarized in table 4.
It is known that antigen processing plays an important role in
shaping the immune dominance. To investigate the effect of
processing on the YFV epitopes, the A*02:01 mice were
inoculated twice with a dose of 10
4 PFU of 17DD YFV strain,
which is attenuated, but able to replicate in mice. The spleens of
the inoculated mice were harvested and the significant T-cell
responses evaluated by ELISPOT using the selected A*02:01
peptides (Table 5). Of the three YFV A*02:01 peptides that
activated the T-cells from the infected mice in vitro, two had
Table 2. ELISPOT results on peptide pool-immunized A*24:02
mice.





WYMWLGARF 19 DENV 119616
MYADDTAGW 415 DENV 12866
TYLALMATF 4 DENV 40615
IFFFLFNIL 19 YFV 1464
DENV-Dengue Virus; YFV-Yellow fever virus; NS-Non structural protein; C-
Capside; PrM-Pre Membrane; E-Envelope.
The results shown is the average and standard deviation of spot forming cells
(SFC)/million splenocytes from two or more mice tested in two or more
separate experiments. All peptides shown were considered positive in at least
two mice according to the criteria described in materials and methods.
doi:10.1371/journal.pone.0026494.t002
Table 3. ELISPOT results on peptide pool-immunized B*07:02
mice.





HPGFTILAL 8 DENV 56640
AVSRGTAKL 6769 YFV 110642
SPGRKNGSF 27 YFV 205650
RVKLSALTL 41 YFV 46620
The results shown is the average and standard deviation of spot forming cells
(SFC)/million splenocytes from two or more mice tested in two or more
separate experiments. All peptides shown were considered positive in at least
two mice according to the criteria described in materials and methods.
doi:10.1371/journal.pone.0026494.t003
Table 1. ELISPOT results on peptide pool-immunized A*02:01
mice.





LLLTLLATV (14597) 43 DENV 28621
KMDIGVPLL (14598) 1 DENV 112619
SMVNGVVRL (14599) 2 DENV 57628
IMAVGLVSL (14601) 92 DENV 56613
ILTDGPERV (14602) 4 DENV 170681
VLNPYMPTV (14604) 1 DENV 166632
SMVNGVVKL (14605) 25 DENV 125646
TLYAVATTV (14606) 1 DENV 81627
VLAPYMPDV (15870) 1 YFV 35649
IIMDEAHFL (15871) 2 YFV 40657
YLIIGILTL (15872) 25 YFV 36635
YMPDVLEKL (15875) 2 YFV 66668
GLFGGLNWI (15876) 1 YFV 2062
LLDKQQFEL (15877) 2 YFV 5564
IMGAVLIWV (15878) 59 YFV 124659
VLAGWLFHV (15879) 1 YFV 64671
WMIHTLEAL (15881) 1 YFV 72654
DENV-Dengue Virus; YFV-Yellow fever virus; NS-Non structural protein; C-
Capside; PrM-Pre Membrane; E-Envelop.
The results shown is the average and standard deviation of spot forming cells
(SFC)/million splenocytes from two or more mice tested in two or more
separate experiments. All peptides shown were considered positive in at least
two mice according to the criteria described in materials and methods.
doi:10.1371/journal.pone.0026494.t001
Table 4. Summary of ELISPOT results on peptide pool-
immunized A*02:01, B*07:02 and A*24:02 mice.
Allele affinity,5n M
5n M ,=affinity
,100 nM Affinity.100 nM
A*02:01 12/14 5/8 0/4
A*24:03 1/2 2/21 1/5
B*07:02 0/4 3/15 1/9
For each allele and affinity range the number of responders are shown together
with the number of tested peptides (after the slash).
doi:10.1371/journal.pone.0026494.t004
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did not show consistent results with the peptide immunization,
now appeared in three separate assays. All three peptides that
elicited responses had an HLA-I binding affinity of 2 nM or less.
The peptides eliciting responses had stronger HLA binding
affinities (average 1.3 nM) than those that did not give a response
(average 156 nM). This difference was, however, only borderline
significant (p=0.068; Wilcoxon rank sum test). The peptides that
elicited a response when using the 17DD YFV strain to vaccinate
also had stronger HLA binding affinities than those that gave
response when using A*02:01 peptides from YFV to vaccinate
(average 47 nM) but this difference was not significant (p=0.23;
Wilcoxon rank sum test). A similar experiment was also performed
in the B*07:02 mice, but no T-cell responses were detected in the
B*07:02 mice inoculated with the 17DD virus. A similar
experiment was not performed in A*24:02 mice since, unfortu-
nately, these mice were no longer available in our laboratory.
When the peptides giving significant responses were tested in
vitro at different concentrations, five peptides (two DENV and
three YFV) that induced responses in A*02:01 mice showed high
functional avidity achieving approximately half the maximal of the
T-cell responses at peptide concentrations as low as 0.1 mg/mL
(Figure 2). The A*02:01 response was specific, since no peptide
from the B*07:02 set (used as negative controls) induced any
response in A*02:01 mice (data not shown). Three of the A*24:03
immunogenic peptides elicited high affinity responses (Figure 3).
Note that all the peptides that were found to be immunogenic in
transgenic B*07:02 mice only activated CTLs at the highest
concentration used, 10 mg/ml. Since we have only made graphs of
peptides that elicited a response at 0.1 mg/ml, they were not
included in any figure.
Discussion
In this study, we identified 179 yellow fever and 158 dengue
peptides as putative HLA-I binders using the NetCTL algorithm.
Approximately 75% of these peptides bound to at least one of the
12 representatives for the HLA-I supertypes with a KD below
500 nM. The immunogenicity of 25 HLA-A*02:01, 28 HLA-
A*24:03 and 28 HLA-B*07:02 binders was tested in three HLA-
transgenic mice models and led to the identification of 17 HLA-
A*02:01, 4 HLA-A*24:03 and 4 HLA-B*07:02 immunogenic
peptides. All except two of the immunogenic peptides had KD
below 100 nM, and the peptides with IC50 below 5 nM were more
likely to be immunogenic. In addition, all the immunogenic
peptides that were identified as having a high functional avidity
(induce more then 50% of maximum response with 0.1 mg/ml of
peptide) had KD below 20 nM.
Considering all three HLA-I types and all 82 tested peptides
together, 22 peptides had KD below 5 nM and 13 (59%) of those
were immunogenic. Considering the 64 peptides that had affinities
to their respective HLA below 100 nM, 23 (36%) induced immune
responses, whereas only two of seventeen (12%) of the peptides
with KD above 100 nM induced immune responses. For each of
the three HLA-I molecules included in this study, we observe an
inverse correlation between the likelihood of a peptide binder of
inducing a CD8 response and the binding affinity. However, this
correlation between the peptide-HLA binding affinity and
immunogenicity in the respective transgenic mice model appears
to differ according to the HLA type. Among the three HLA-I types
evaluated, A*02:01 showed the highest correlation between HLA
binding affinity and immunogenicity, since 86% of the peptides
with KD below 5 nM induced responses. The reason we did not
see a significant correlation for A*24:03 and B*07:02 may be that
we found relatively fewer responding peptides for these alleles as
compared to A*02:01.
These differences in correlation between HLA binding affinity
and immunogenicity may be due to differences in the levels of
expression of the HLA molecule in the transgenic mice model or
other artifacts of these artificial animal models. However, it could
Table 5. ELISPOT results on 17DD YFV vaccine-immunized
A*02:01 mice.





GLFGGLNWI 1 YFV 402620
VLAGWLFHV 1 YFV 67625
GLYGNGILV 2 YFV 1865
The results shown is the average and standard deviation of spot forming cells
(SFC)/million splenocytes of two or more mice tested in two or more separate
experiments. All peptides shown were considered positive in at least two mice
according to the criteria described in materials and methods.
doi:10.1371/journal.pone.0026494.t005
Figure 2. ELISPOT results in 9 mice vaccinated with either A*02:01 dengue peptide pool or YFV 17DD vaccine in A*02:01 mice.
Peptides positive at concentration 0.1 mg/mL and greater are shown. Results are depicted as percentage of spot-forming cells/million cells of each
peptide at 10 mg/mL.
doi:10.1371/journal.pone.0026494.g002
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specific HLA alleles with the CD8 molecules or with the T-cell
receptor that would lead to different requirements of MHC-
peptide affinities for optimum T-cell activation. If this is true, it is
possible that different HLA alleles preferentially induce responses
to peptides with distinct ranges of MHC-peptide binding affinities.
This latter speculation is in accordance with earlier observations
by Rao et al. [29].
In conclusion, we have described the predicted top binding
peptides, all highly conserved in YFV and DENV, for the 12
HLA-I supertypes (see table S2). The potential immunogenicity of
these peptides was evaluated in mice models transgenic for three
different HLA types and more than half of the peptides with KD
below 5 nM for the HLA-1 molecule in question were indeed
immunogenic.
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